SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Tobira Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Tobira Therapeutics, Inc. (NASDAQCM:TBRA) (“Tobira”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On July 25, 2016, Tobira announced that its Phase 2b trial for cenicriviroc, a liver disease treatment, failed to meet its primary endpoint. Upon this news, shares of Tobira were down 58% on intraday trading on July 25, 2016. To obtain additional information, go to:

http://zlk.9nl.com/tobira-therapeutics-tbra

or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone].

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.